Factors influencing plasma nevirapine levels: A study in HIV-infected children on generic antiretroviral treatment in India

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 6, 2011, Pages 1354-1359

  Swaminathan, Soumya ^a   Ramachandran, Geetha ^a   Kupparam, Hemanth Kumar Agibothu ^a   Mahalingam, Vasantha ^a   Soundararajan, Lakshmi ^a   Kannabiran, Bhavani Perumal ^a   Navaneethapandian, Poorana Ganga Devi ^a   Shah, Ira ^b   Karunaianandham, Ramesh ^a   Sikhamani, Rajasekaran ^c,d  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^b B J WADIA HOSPITAL FOR CHILDREN   (India)

^c Government Hospital for Thoracic Medicine   (India)

^d National AIDS Control Organisation   (India)

Author keywords

CYP2B6 516G> T polymorphism; Nutritional status; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2B6; GENERIC DRUG; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE;

AGE; ARTICLE; BODY HEIGHT; BODY SURFACE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; FEMALE; GENDER; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; GROWTH RETARDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUTRITIONAL STATUS; PRESCHOOL CHILD; STEADY STATE; TABLET; TREATMENT DURATION;

AGE FACTORS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARYL HYDROCARBON HYDROXYLASES; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HIV INFECTIONS; HUMANS; INDIA; INFANT; MALE; MODELS, STATISTICAL; NEVIRAPINE; OXIDOREDUCTASES, N-DEMETHYLATING; PLASMA; POLYMORPHISM, GENETIC;

EID: 79956031034     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr075     Document Type: Article

References (23)

1. National AIDS Control Organisation. http://www.nacoonline.org/quick-links/HIV-data (1 January 2011, date last accessed).
2. WHO. Antiretroviral Therapy of HIV Infections in Infants and Children: Towards Universal Access. 2008. http://www.who.int/hiv/pub/guidelines/art/en (10 April 2010, date last accessed).
3. Menson EN, Walker AS, Sharland M. et al. for the Collaborative HIV Pediatric Study Steering Committee. Under-dosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. Brit Med J 2006; 332: 1183-7.
4. National AIDS Control Organisation. Guidelines for HIV Care and Treatment in Infants and Children, November 2006. http://www.nacoonline.org/quick-links/publication/treatment-care-support (3 April 2010, date last accessed).
5. Ellis JC, L'homme RF, Ewings FM. et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007; 12: 253-60.
6. L'Homme RFA, Kabamba D, Ewings FM. et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on pediatric fixed-dose combination tablets. AIDS 2008; 22: 557-65.
7. WHO. Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee. Technical Report Series No. 854. 1995. http://www.who.int/childgrowth/publications/physical_status/en/index.html (6 April 2010, date last accessed).
8. Ramachandran G, Hemanth Kumar AK, Kumaraswami V. et al. Simple liquid chromatography method for simultaneous determination of zidovudine and nevirapine in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 843: 339-44.
9. Ariyoshi N, Miyazaki M, Toide K. et al. A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation. Biochem Biophys Res Commun 2001; 281: 1256-60.
10. Anderson GD, Lynn AM. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy 2009; 29: 680-90.
11. Anderson GD. Developmental pharmacokinetics. Sem Pediatr Neurol 2010; 17: 208-13.
12. Poerksen G, Pollock L, Moons P. et al. Steady state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets. Antivir Ther 2010; 15: 343-50.
13. Mulenga V, Fillekes Q, Kabamba D. et al. Pharmacokinetics of nevirapine in 3- and 6-kg HIV-infected infants taking pediatric fixed-dose combination tablets. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009. Abstract 881. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
14. Pollock L, Else L, Poerksen G. et al. Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving adult fixed-dose combination tablets. J Antimicrob Chemother 2009; 64: 1251-9.
15. Krishnaswamy K. Drug metabolism and pharmacokinetics in malnourished children. Clin Pharmacokinet 1989; 17 Suppl 1: 68-88.
16. Padmapriyadarsini C, Pooranagangadevi N, Chandrasekaran K. et al. Prevalence of underweight, stunting and wasting among children infected with human immunodeficiency virus in south India. Int J Pediatr 2009; 2009: 837627 (doi:10.1155/2009/837627).
17. Saitoh A, Sarles E, Capparelli E. et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007; 21: 2191-9.
18. Ramachandran G, Ramesh K, Hemanth Kumar AK. et al. Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. J Antimicrob Chemother 2009; 63: 841-3.
19. Mahungu T, Smith C, Turner F. et al. Cytochrome P450 2B6 516G to T is associated with plasma concentrations of nevirapine at both 200mg and 400mg once daily in an ethnically diverse population. HIV Med 2009; 10: 310-7.
20. Chokephaibulkit K, Cressey TR, Prasituebsai W. et al. Nevirapine pharmacokinetics in Thai children receiving either an adult or pediatric fixed-dose combination of stavudine, lamivudine and nevirapine. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008. Abstract 577. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
21. Chokephaibulkit K, Plipat N, Cressey TR. et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS 2005; 19: 1495-9.
22. Burger D, Ewings F, Kabamba D. et al. Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine and lamivudine in HIV-infected children treated with paediatric fixed dose combination tablets. Ther Drug Monit 2010: 32: 369-72.
23. Ramachandran G, Hemanth Kumar AK, Rajasekaran S. et al. Steady state pharmacokinetics of nevirapine in HIV-infected adults in India. J Int Assoc Physicians AIDS Care 2007; 6: 251-4.